trending Market Intelligence /marketintelligence/en/news-insights/trending/s41oesvqu7y0yoxaydt4gg2 content esgSubNav
In This List

PDL BioPharma no longer pursuing Neos Therapeutics

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy


PDL BioPharma no longer pursuing Neos Therapeutics

PDL BioPharma Inc. said it is no longer looking to acquire Neos Therapeutics Inc.

The Incline Village, Nev.-based biotech company had offered to buy Texas-based Neos for $10.25 per share in cash, but its offer had been rejected by the target company's board.

"While we believe we have provided a compelling opportunity for Neos' shareholders, we were unable to agree on terms that were in the best interest of our shareholders. We continue to pursue other opportunities and be disciplined in the process," PDL CEO John McLaughlin said in a statement.